Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202830 | 0.88 | MEN1 (0.53) | MEN1KMT2AGAAP2RX4L3MBTL1 | |
| SCHEMBL3203044 | 0.79 | ALDH1A1 (0.48) | MEN1KMT2AGAAL3MBTL1LMNA | |
| SCHEMBL2087105 | 0.78 | ALDH1A1 (0.36) | MEN1KMT2AGAAL3MBTL1LMNA | |
| SCHEMBL3220778 | 0.74 | MEN1 (0.43) | MEN1KMT2AGAAP2RX4SMN1; SMN2 | |
| SCHEMBL3221008 | 0.70 | MEN1 (0.50) | MEN1KMT2AGAAP2RX4SMN1; SMN2 | |
| SCHEMBL3210120 | 0.70 | KDM4E (0.49) | MEN1KMT2AGAAP2RX4SMN1; SMN2 | |
| SCHEMBL23997395 | 0.70 | MEN1 (0.59) | MEN1KMT2AGAAL3MBTL1SMN1; SMN2 | |
| SCHEMBL30336707 | 0.70 | MEN1 (0.59) | MEN1KMT2AGAAL3MBTL1SMN1; SMN2 | |
| SCHEMBL28492451 | 0.70 | MEN1 (0.56) | MEN1KMT2AGAAL3MBTL1SMN1; SMN2 | |
| SCHEMBL25232919 | 0.69 | CCR2 (0.55) | MEN1KMT2AGAAL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030554-B1 | PIPERIDINE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-02-28 | — | — | EP | claimed |
| EP-3030554-A1 | PIPERIDINE UREA DERIVATIVES | Merck Patent GmbH (DE) | 2016-06-15 | — | — | EP | claimed |
| WO-2015018475-A1 | PIPERIDINE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-12 | — | — | WO | claimed |
| EP-2430023-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | claimed |
| WO-2010130665-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | WO | claimed |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | US | claimed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-3030554-B1 | PIPERIDINE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9770446-B2 | Piperidine urea derivatives | MERCK PATENT GMBH (DE) | 2017-09-26 | — | — | US | disclosed |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| EP-2088861-A2 | BENZIMIDAZOLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008051533-A2 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1838674-A2 | HETEROARYL SULFONAMIDES AND CCR2 | ChemoCentryx Inc (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20060173019-A1 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006076644-A2 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173019-A1 | Heteroaryl sulfonamides and CCR2 | CCR2, CXCR2, CCR1 | MEN1 4873/4885KMT2A 1875/4885GAA 4664/4885 |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | MEN1 4873/4885KMT2A 2475/4885GAA 4469/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | MEN1 4680/4885KMT2A 3284/4885GAA 4842/4885 |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | MEN1 4873/4885KMT2A 2475/4885GAA 4469/4885 |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | MEN1 4873/4885KMT2A 2475/4885GAA 4469/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | MEN1 4873/4885KMT2A 2475/4885GAA 4469/4885 |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | GPR119, LDLR, LPL | MEN1 2464/4885KMT2A 830/4885GAA 792/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | MEN1 4873/4885KMT2A 2475/4885GAA 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.